Korean J Gastroenterol.  2010 Jul;56(1):39-44. 10.4166/kjg.2010.56.1.39.

Successful Resection of Locally Advanced Gastrointestinal Stromal Tumor of the Ampulla of Vater after Treatment with Imatinib

• Park JE
• Dong SH
• Cho KH
• Jang JY
• Kim HJ
• Kim BH
• Chang YW
• Chang R

• KMID: 1775877
• DOI: http://doi.org/10.4166/kjg.2010.56.1.39

Abstract

Gastrointestinal stromal tumor (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract arising from Cajal's cells, expressing CD 117. The standard treatment for primary GIST is complete surgical resection. Imatinib mesylate, a specific tyrosine kinase inhibitor, is effective against locally advanced and metastatic GIST. There are several reports of the effect of preoperative imatinib in patients with unresectable and locally advanced primary GIST. We report a case of unresectable primary GIST of the ampulla of Vater, which we were able to completely resect after treatment with a dosage of imatinib 400 mg daily for 5 months. Twelve months later, the patient was treated with imatinib and doing well with no evidence of recurrence.

Keyword

Gastrointestinal stromal tumor; Ampulla of Vater; Imatinib; Surgery

MeSH Terms

Ampulla of Vater/*pathology
Antineoplastic Agents/*therapeutic use
Duodenoscopy
Gastrointestinal Stromal Tumors/diagnosis/drug therapy/*surgery
Humans
Male
Middle Aged
Piperazines/*therapeutic use
Pyrimidines/*therapeutic use
Tomography, X-Ray Computed

Figure

• 

  Fig. 1. Abdominal CT scan findings. (A) Enhanced CT scan showed a 7.6×5.3 cm sized mass in the duodenal second portion invading the pancreatic head and inferior vena cava. (B) Follow-up CT scan 3 months after treatment with imatinib showed a remarkable reduction in the size of the tumor, to 4.4×3.2 cm. (C) Five months after the treatment, CT scan revealed a slightly reduction in the tumor size, to 4×2.8 cm.

• 

  Fig. 2. Duodenoscopic finding showed that a huge mass with central ulceration at the ampulla of Vater.

• 

  Fig. 3. Endoscopic retrograde chol-angiographic findigs. (A) Cholan-giogram showed a metallic stent (10×4 cm), which was placed at the distal common bile duct. (B) The stent was seen at the ampulla with ulcerative mass on endoscopic view.

• 

  Fig. 4. Follow-up duodenoscopic finding 3 months after treatment with imatinib showed that the previously noted nodular mass around metal stent was almost disappeared and only small nodular lesion with granular surface was seen around the im-beded stent opening.

• 

  Fig. 5. (A) Gross finding of the resected tumor showed submucosal whitish mass-like lesion with focal myxoid appearance (3×1.8×2 cm) in the ampulla of Vater, which was extending into the pancreas parenchyme. (B) Microscopic findings revealed well circumscribed lobulated tumor tissue, consisted of interlacing or whorling of spindle cells with intervening hyalinized stroma. It showed moderate to high cellularity and mitotic figures were rarely seen ＜5/10HPFs (H&E, ×400). (C, D) Immunohistochemical stainings showed positivity for CD 34 and CD 117.

Reference

1. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol. 2000; 7:705–712.

2. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999; 30:1213–1220.

3. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998; 152:1259–1269.

4. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiq-uitous feature of gastrointestinal stromal tumors. Cancer Res. 2001; 61:8118–8121.

5. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002; 33:459–465.

6. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005; 16:566–578.

7. Choi WH, Kim S, Hyung WJ, et al. Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. Yonsei Med J. 2009; 50:437–440.

8. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol. 1999; 23:82–87.

9. Greenson JK. Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol. 2003; 16:366–375.

10. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23:70–83.

11. Yang WL, Yu JR, Wu YJ, et al. Duodenal gastrointestinal stromal tumor: clinical, pathologic, immunohistochemical characteristics, and surgical prognosis. J Surg Oncol. 2009; 100:606–610.

12. Kim SH, Kim JH, Baik GH, et al. Malignant gastrointestinal stromal tumor of the ampulla of Vater: a case report. Korean J Gastroenterol. 2004; 43:66–70.

13. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006; 244:176–184.

14. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006; 130:1466–1478.

15. Demetti GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347:472–480.

16. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007; 14:14–24.

17. Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol. 2009; 35:739–745.

18. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose Imatinib: randomized trial. Lancet. 2004; 364:1127–1134.

19. Haller F, Detken S, Schulten HJ, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol. 2007; 14:526–532.

20. Bü mming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer. 2003; 89:460–464.